SpaceX Joins Nasdaq 100; Crinetics Pharmaceuticals Rises on Acquisition News

FISV shares have recorded a strong 8.95% gain in the last 24 hours, with the RSI at 65.8, approaching overbought territory. While the MACD remains above the signal line, momentum may slow somewhat. No direct news related to FISV appears in the headlines, so additional catalysts are needed to sustain the rally. In the short term, consolidation or a slight pullback may follow the surge.

NDX fell 3.97% in the last 24 hours to 29,062.93, with its RSI at 34.04, nearing oversold territory. The MACD line remains below the signal line and in negative territory, indicating weak short-term momentum. The price is trading below its 20-day and 50-day moving averages (29,568.54 and 29,629.04, respectively), which may act as resistance levels. While SpaceX's inclusion in the Nasdaq 100 is a positive development, the overall technical outlook remains weak, and the downtrend could persist. In the short term, the 29,000 level may be tested, though a potential rebound is possible given oversold conditions.

Although JPMorgan (JPM) shares rose 3.26% in the last close, the news headlines are not directly related to the banking sector. Developments such as SpaceX joining the Nasdaq 100 and the acquisition of Crinetics Pharmaceuticals are outside JPM's operational scope. Technical indicators show the RSI at 60.8, in neutral territory, while the MACD is giving a bullish signal. In the short term, these news items are not expected to have a significant impact on JPM, hence the outlook is assessed as neutral.

BAC shares have risen 5.45% in the last 24 hours, with the RSI at 69.3, approaching overbought territory. Although the MACD is positive and the price remains above short-term averages, supporting the upward trend, the news headline is not directly related to BAC, so the market impact may be limited. For the uptrend to continue in the short term, a new catalyst is needed; therefore, a neutral outlook is more appropriate.